Gyre Pharma unit acquires rights to generic Nintedanib, competing drug to ETUARY, for IPF/category

GYRE THERAPEUTICS, INC.

Gyre Pharmaceuticals (GYRE subsidiary) signed a comprehensive agreement with Jiangsu Wangao to acquire rights to generic Nintedanib, a competitor to ETUARY.
ETUARY sales grew 15-20% annually; IPF drug market in China expected to reach ¥127.4B by 2031 per Frost & Sullivan.
Annual sales of Nintedanib expected to exceed ¥4 billion if not included in centralized procurement system.
Acquisition enhances Gyre's leading position in pulmonary fibrosis and adds a new product for IPF and similar diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.